NCT01729403已完成2 期
A Single Centre, Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus (T2D) Who Are Inadequately Controlled With Metformin Monotherapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 57
- 主要终点
- Change in whole-body insulin sensitivity as assessed by M-value (Insulin-stimulated glucose disposal rate)
研究概览
简要总结
This single-center, randomized, double-blind, placebo-controlled study will evaluate the effect of aleglitazar on insulin sensitivity in patients with type 2 diabetes mellitus who are inadequately controlled on metformin monotherapy. Patients will be randomized to receive either aleglitazar 150 mcg or placebo orally daily for 16 weeks, in addition to their existing dose and regimen of metformin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 30 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients, 30 to 70 years of age inclusive at screening
- •Type 2 diabetes mellitus patients treated with stable metformin therapy for at least 12 weeks prior to screening; metformin dose should not exceed the maximum dose specified in the label
- •HbA1c >/= 6.5% and </= 9% at screening and baseline
- •Fasting plasma glucose </= 13.3 mmol/L (</= 240 mg/dl) at screening and baseline
- •Body mass index (BMI) >/= 25 at screening; BMI >/= 27 for subjects with HbA1c < 7%
- •Stable weight +/- 5% for at least 12 weeks prior to screening
排除标准
- •Women who are pregnant, intending to become pregnant during the study period, currently lactating women, or women of child-bearing potential not using highly effective, medically approved birth control methods
- •Diagnosis or history of type 1 diabetes mellitus, diabetes resulting from pancreatic injury, or secondary forms of diabetes
- •Acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma within the past 6 months
- •Any previous treatment with a thiazolidinedione or with a dual peroxisome proliferator activated receptor (PPAR) agonist
- •Any body weight lowering or lipoprotein-modifying therapy (e.g. fibrates) within 12 weeks prior to screening with the exception of stable (>/= 1 month) statin therapy
- •History of bariatric surgery or currently undergoing evaluation for bariatric surgery
- •Prior intolerance to fibrate
- •Treatment with any anti-diabetic medication other than metformin in the last 12 weeks prior to screening and/or herbal/over-the-counter preparations that may affect glycemic control within 12 weeks prior to screening
- •Clinically apparent liver disease
- •Positive for hepatitis B, hepatitis C or HIV infection
- •Clinical evidence of anemia
- •Symptomatic congestive heart failure (New York Heart Association Class II-IV) at screening
- •Myocardial infarction, acute coronary syndrome, or transient ischemic attack/stroke within 6 months prior to screening
- •Known macular edema at screening or prior to screening visit
- •Uncontrolled hypertension despite stable (for at least 4 weeks) anti-hypertensive treatment
- •Diagnosed and/or treated malignancy (except for treated cases of basal cell skin cancer, in situ carcinoma of the cervix or in situ prostate cancer) within the past 5 years
- •Chronic oral or parenteral corticosteroid treatment (> 2 weeks) within 3 months prior to screening
- •History of active substance abuse (including alcohol) within the past 2 years or positive test result for drugs of abuse or alcohol prior to first dosing
- •Presence of any absolute or relative contraindication for the conduct of magnetic resonance imaging (MRI) investigation
研究组 & 干预措施
Aleglitazar
Experimental
干预措施: aleglitazar (Drug)
Placebo
Placebo Comparator
干预措施: placebo (Drug)
Aleglitazar
Experimental
干预措施: metformin (Drug)
Placebo
Placebo Comparator
干预措施: metformin (Drug)
结局指标
主要结局
Change in whole-body insulin sensitivity as assessed by M-value (Insulin-stimulated glucose disposal rate)
时间窗: from baseline to Week 16
次要结局
- Change in hepatic fat content measured by magnetic resonance spectroscopy (MRI)(from baseline to Week 16)
- Change in mean 24h blood pressure(from baseline to Week 16)
- Change in hepatic insulin sensitivity (basal index of hepatic insulin resistance)(from baseline to Week 16)
- Change in parameters of beta cell function (first and second phase insulin secretion)(from baseline to Week 16)
- Change in lipid profile(from baseline to Week 16)
- Change in fat content/distribution in the abdominal region measured by MRI(from baseline to Week 16)
- Change in HbA1c(from baseline to Week 16)
- Change in total body fat content measured by air displacement phlethysmography(from baseline to Week 16)
- Safety: Incidence of adverse events(22 weeks)
- Change in homeostatic indexes of insulin sensitivity assessed by Homeostasis Model Assessment for Insulin Sensitivity (HOMA-IS)(from baseline to Week 16)
- Change in markers of cardiovascular risk (high sensitivity C-reactive protein, adiponectin, free fatty acid)(from baseline to Week 16)
研究者
相似试验
已完成
1 期
A Study of RO6799477 in Healthy VolunteersHealthy VolunteerNCT01893437Hoffmann-La Roche27
已完成
2 期
Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese ChildrenMalariaNCT03521973Sanaria Inc.200
撤回
2 期
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Plaque Psoriasis in AdultsPlaque PsoriasisNCT02993328Santalis Pharmaceuticals, Inc.
已完成
1 期
A Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese SubjectsHealthy SubjectsNCT02289599Eisai Co., Ltd.24
已完成
1 期
Safety and Pharmacokinetic Trial in Healthy HIV-Negative Women to Assess the Delivery of Dapivirine From a Vaginal RingHIV InfectionsNCT02920827International Partnership for Microbicides, Inc.16